New HPLC Method with Experimental Design and Fluorescence Detection for Analytical Study of Antihypertensive Mixture,Amlodipine and Valsartan

New HPLC method was developed for determination of amlodipine and valsartan in their binary mixture as a part of routine control of combined formulations. The method was validated to meet official requirements including selectivity, stability, linearity, precision and accuracy. Chromatography was carried out using a LiChrospher RP-18 column, a mixture containing acetonitrile, phosphate buffer of pH 3.5 and methanol (45:45:10, v/v/v) and new fluorescence detection at 255 nm for excitation and 448 nm for emission. The effect of methanol content, pH of the buffer, flow rate, detection wavelengths and column temperature was estimated in robustness study, according to a plan defined by the Plackett-Burman design. For identification of significant effects, both graphical and statistical methods were used. Ro-bustness for dissolution test was checked estimating the effects of paddle speed, temperature and pH of dissolution medium. The method was proved to complying with all official guidelines. Therefore, it is suitable for determination of amlodipine and valsartan in their binary mixtures for different analytical and pharmaceutical purposes.

RP-HPLC Method for the Simultaneous Determination of Lisinopril and NSAIDs in API, Pharmaceutical Formulations and Human Serum

High performance liquid chromatographic method was developed valdated and applied for the simultaneous determi- nation of lisinopril and NSAIDs in bulk, pharmaceuticals formulations and human serum. A Purospher star C18 (5 μm, 25 × 0.46 cm) column was used with mobile phase consisting of methanol: water: acetonitrile (80:17.5:2.5 v/v, pH 3.0) and quantitative evaluation was performed at 225 nm with a flow rate of 1.0 mL?min–1. The retention time of lisinopril was 2.2 min while naproxen, flurbiprofen, diclofenac sodium and mefenamic acid were found to be 4.0, 4.5, 5.0 and 6.7 min respectively. Suitability of this method for the quantitative determination of the drugs was proved by validation in accordance with the requirements laid down by International Conference on Harmonization (ICH) guidelines. The method is selective, precise, accurate and can be used for analysis of pharmaceutical preparations in quality control and clinical laboratories.

Stability Indicating HPLC Method for Quantification of Solifenacin Succinate &Tamsulosin Hydrochloride along with Its Impurities in Tablet Dosage Form

A novel stability-indicating RP-HPLC method was developed and validated for simultaneous determination of Solifenacin Succinate & Tamsulosin Hydrochloride and its impurities in tablet dosage form. The method was developed using L1 column with gradient using the mobile phase consist of solvent-A (pH = 6.6, phosphate buffer + 0.5% Triethylamine) and solvent-B (90% Acetonitrile). The eluted compounds were monitored at 225 nm. Solifenacin Succinate & Tamsulosin Hydrochloride was subjected to oxidative, acid, base, hydrolytic, thermal and photolytic stress conditions. The developed method was validated as per ICH guidelines with respect to specificity, linearity, limit of detection, limit of quantitation, accuracy, precision and robustness. The limit of quantification results was ranged from 0.135 - 0.221 μg/mL for Solifenacin Succinate impurities and 0.043 - 0.090 μg/mL for Tamsulosin Hydrochloride impurities. This method is suitable for the estimation of impurities and assay of Solifenacin Succinate & Tamsulosin Hydrochloride in tablets dosage form.

Development and Application of a Validated HPLC Method for the Determination of Clindamycin Palmitate Hydrochloride in Marketed Drug Products: An Optimization of the Current USP Methodology for Assay

A simple efficient isocratic reversed-phase HPLC method was developed and validated for the determination of clindamycin palmitate hydrochloride (CPH) and its commercially available oral solution products. Separation was achieved on a Phenomenex Zorbax (Luna) cyano column (150 × 4.6 mm, 5 μm) with a Phenomenex cyano guard cartridge (4 × 3.0 mm) on Agilent 1050 series HPLC system. CPH and its resolution standard lincomycin were eluted isocratically at a flow rate of 1 mL/min with a simplified mobile phase (potassium phosphate buffer (5 mM, pH 3.0)—acetonitrile—tetrahydrofuran (20:75:5, v/v/v)) and detected at 210 nm. The column was maintained at 25?C. The method was validated according to USP category I requirements. Robustness and forced degradation studies were also conducted. CPH marketed drug products were obtained from a drug distributor and assayed for potency using the validated method. Validation acceptance criteria were met in all cases. The analytical range for CPH was 15 - 500 μg/mL and the linearity was r2 > 0.999 over three days. The method was determined to be specific and robust. Both accuracy (92.0% - 103.8%) and precision (0.67% - 1.52%) were established across the analytical range for low, intermediate and high QC concentrations. Method applicability was demonstrated by analyzing two marketed products of CPH, in which results showed potency >98%. The method was determined to be an enhancement over the current USP methodology for assay as a result of increased efficiency, reduced organic solvents and the elimination of matrix modifiers. This method was successfully applied for the quality assessment of: 1) currently marketed drug products and 2) will in future assess the product quality of novel dosage forms of CPH for pediatric use.

Stability Indicating RP-HPLC Method for Quantification of Impurities in Valsartan and Hydrochlorothiazide FDC Tablet Dosage Form

A stability-indicating RP-HPLC method has been developed and validated for simultaneous determination of Valsartan & Hydrochlorothiazide and their impurities in FDC (Fixed Dose Combination) tablet dosage form. The method was developed using L1 column (250 × 4.6 mm;5 μm) with gradient elution using the mobile phase consisting of solvent-A (0.1% Ortho phosphoric acid) and solvent-B (100% Acetonitrile);the gradient program (Tmin/%B) was set as 0/10, 5/10, 20/60, 40/60, 41/10 and 50/10. The eluted compounds were monitored at 265 nm. The developed method was validated as per ICH guidelines with respect to specificity, linearity, limit of detection, limit of quantitation, accuracy, precision and robustness. The influence of Acid, Alkaline, Oxidative, Photolytic, Thermal and Humidity stress conditions, on drug product was studied. The limit of quantification results of Valsartan, Hydrochlorothiazide and their impurities are, VAL: 0.303 μg/mL, HCTZ: 0.019 μg/mL, VAL RC-B: 0.085 μg/mL, VAL RC-C: 0.327 μg/mL, HCT RC-A: 0.017 μg/mL, CTZ: 0.080 μg/mL and 5-Chloro HCT: 0.047 μg/mL. The proposed method is suitable for the estimation of Valsartan & Hydrochlorothiazide impurities in tablets dosage form.

Validation of a HPLC Method for Quantification of Thiamine and Its Phosphate Esters in Rat Brain Tissue

The present data show a fast and efficient biological sample processing method for the extraction of thiamine (vitamin B1) and its mono-(TMP) and di-(TDP) phosphate esters from hippocampus, thalamus and prefrontal cortex (PFC) and blood sample of the rodents. In addition, using the hippocampus and standards of these three compounds we validated an isocratic fluorescence HPLC procedure for a simultaneous detection of them in a single chromatogram within a total run time of about 12 min. Reproducibility for TDP, TMP and B1 was 2.66%, 4.50% and 7.43% (intraday) and 37.54%, 25.39% and 25.87% (interday), respectively. Recovery assays were between 96.0% and 101.7%. The calibration curves were linear and the concentrations of the three compounds, all in nanomolar range, were determined in the brain areas and in the blood samples. When compared to the current methods in the literature, this new method provides information on essential variables, such as linearity range and limit of detection, reproducibility and stability of thiamine, TMP and TDP in rat brain samples. The present data on sample processing and B1 and its phosphate ester level determinations are the first to be validated using hippocampus samples of rats.

HPLC-UV法测定舒肝和胃丸中α-香附酮和香附烯酮的含量

目的:建立舒肝和胃丸中α-香附酮和香附烯酮的高效液相色谱(HPLC-UV)含量测定法,为该制剂中醋香附含量的质量控制提供依据。方法:对舒肝和胃丸中α-香附酮和香附烯酮同时进行含量测定。采用Agilent ZORBAX SB-C18色谱柱(4.6 mm×250 mm,5μm),流动相为甲醇和水(65∶35),流速1.0 mL·min^(-1),检测波长254 nm,柱温30℃,进样量5μL。结果:采用该方法得到的舒肝和胃丸色谱图中,α-香附酮和香附烯酮色谱峰与相邻色谱峰分离效果较好,满足含量测定的要求;指标性成分α-香附酮、香附烯酮分别在0.08036~0.80360μg、0.2112~2.1120μg范围内线性关系良好,相关系数均为1.000;平均加标回收率分别为102.0%(RSD:1.6%,n=6),102.4%(RSD:2.0%,n=6);稳定性(24 h)、重复性、精密度良好。结论:本研究建立的α-香附酮和香附烯酮HPLC-UV含量测定方法简单、快捷、准确,可为舒肝和胃丸中醋香附含量的控制提供依据。

HPLC法测定乳苣不同部位菊苣酸含量

采用超声法提取乳苣不同部位总多酚,建立了测定乳苣不同部位菊苣酸含量的HPLC法,色谱条件为:岛津LC-16型高效液相色谱仪,SPD检测器,C18色谱柱(4.6 mm×150 mm,5μm),柱温为40℃,流动相为甲醇-0.1%磷酸,梯度洗脱,流速为1.0 mL·min^(-1),检测波长为280 nm,进样量为10μL。结果表明,菊苣酸浓度在11.6~58.0μg·mL^(-1)范围内与峰面积线性关系良好(R^(2)=0.9994),平均加标回收率为95.30%(n=6);乳苣根、茎、叶、全草中菊苣酸含量分别为23.70 mg·g^(-1)、37.20 mg·g^(-1)、114.24 mg·g^(-1)、102.50 mg·g^(-1),乳苣不同部位菊苣酸含量大小顺序为:叶>全草>茎>根。该方法简便、快速、准确,适用于乳苣中菊苣酸含量的测定。

HPLC法测定葫芦七不同部位中7种倍半萜的含量

[目的]建立HPLC法测定葫芦七不同部位(根、茎、叶)中7种倍半萜类化合物的含量。[方法]采用Kromasil C_(18)(4.6 mm×250 mm,5μm)色谱柱,流动相为乙腈-水(40∶60);柱温35℃;检测波长240 nm;进样体积10μL。[结果]7种被测成分在测定质量浓度范围内线性关系良好(R^(2)≥0.9990);平均回收率在95.18%~97.61%,RSD在0.41%~1.60%;被检测的7种倍半萜类成分在葫芦七根、茎、叶不同部位中的含量差异明显,根中所含化合物的种类相对较多,含量相对较高。[结论]该方法快速、简便、准确,可用于葫芦七药材的质量控制。

Robustness Study and Superior Method Development and Validation for Analytical Assay Method of Atropine Sulfate in Pharmaceutical Ophthalmic Solution

Background: The robustness is a measurement of an analytical chemical method and its ability to contain unaffected by little with deliberate variation of analytical chemical method parameters. The analytical chemical method variation parameters are based on pH variability of buffer solution of mobile phase, organic ratio composition changes, stationary phase (column) manufacture, brand name and lot number variation;flow rate variation and temperature variation of chromatographic system. The analytical chemical method for assay of Atropine Sulfate conducted for robustness evaluation. The typical variation considered for mobile phase organic ratio change, change of pH, change of temperature, change of flow rate, change of column etc. Purpose: The aim of this study is to develop a cost effective, short run time and robust analytical chemical method for the assay quantification of Atropine in Pharmaceutical Ophthalmic Solution. This will help to make analytical decisions quickly for research and development scientists as well as will help with quality control product release for patient consumption. This analytical method will help to meet the market demand through quick quality control test of Atropine Ophthalmic Solution and it is very easy for maintaining (GDP) good documentation practices within the shortest period of time. Method: HPLC method has been selected for developing superior method to Compendial method. Both the compendial HPLC method and developed HPLC method was run into the same HPLC system to prove the superiority of developed method. Sensitivity, precision, reproducibility, accuracy parameters were considered for superiority of method. Mobile phase ratio change, pH of buffer solution, change of stationary phase temperature, change of flow rate and change of column were taken into consideration for robustness study of the developed method. Results: The limit of quantitation (LOQ) of developed method was much low than the compendial method. The % RSD for the six sample assay of developed method was 0.4% where the % RSD of the compendial method was 1.2%. The reproducibility between two analysts was 100.4% for developed method on the contrary the compendial method was 98.4%.

HPLC法测定44%砜吡草唑·异丙隆悬浮剂中有效成分含量

建立了一种同柱分离检测44%砜吡草唑·异丙隆悬浮剂中有效成分的高效液相色谱定量方法,确定的色谱条件为250 mm×4.6 mm ODS-C18不锈钢色谱柱和紫外检测器,柱温30℃,甲醇+水溶液(60︰40,体积比)为流动相,检测波长为220 nm。结果表明:在设定的质量浓度范围内,砜吡草唑和异丙隆的线性相关系数r均为0.9999,变异系数分别为1.07%和0.1421%,回收率分别为99.78%和99.50%,说明该方法操作简单、分离效果好,线性关系、准确度和精密度均符合分析的基本要求,可用于制剂产品中砜吡草唑和异丙隆的质量控制。

HPLC-MS法同时测定大鼠血浆中那格列奈及其主要代谢物M1

目的建立同时测定那格列奈及其主要代谢物M1的HPLC-MS方法。方法血浆样品经过乙酸乙酯萃取,以非那西丁为内标。色谱采用岛津C18柱(5μm,4.6 mm×250 mm)分离,流动相为0.1%甲酸溶液与乙腈,梯度洗脱,流速0.2 mL/min。质谱采用选择性离子监测(SIM)阳离子模式,检测对象[M+H]^(+)为:那格列奈318.2,代谢物M1334.1,非那西丁180.1。结果标准曲线线性范围为0.0625~8μg/mL那格列奈,M1为0.0313~4μg/mL。日内及日间准确度和精密度变异均<10%,血浆样品稳定性良好,提取回收率均>96%,基质效应<5%。结论本方法稳定性好、灵敏度高、重现性好,可应用于各类生物样本中那格列奈及其代谢物M1的生物等效性与药物代谢动力学研究。

HPLC-柱后衍生荧光法测定水产品中河豚毒素含量结果的不确定度评定

通过建立HPLC-柱后衍生荧光法测定水产品中河豚毒素含量的不确定度评定方法,量化分析测定结果的不确定度分量,并对各分量相对贡献进行比较。结果表明:测定结果的不确定度主要来源于标准品的校准过程、样品称量、实验过程移取及定容、样品重复实验误差、前处理过程中的回收率不同等。其中校准不确定度中标准溶液配制的不确定度贡献最多,称样量不确定度最小;当水产品中河豚毒素的含量为90.6μg/kg时,其扩展不确定度为0.69μg/kg(包含因子k=2)。

HPLC法测定注射用头孢他啶含量的不确定度评定

目的对HPLC法测定注射用头孢他啶的不确定度进行评定和分析,完善药品检测实验室风险控制体系。方法建立HPLC法测定注射用头孢他啶含量的数学模型,分析测量不确定度来源,并对各分量进行量化分析,评估实验室存在的风险指标。结果HPLC法测定注射用头孢他啶含量的合成相对不确定度为0.962%,扩展不确定度为1.92%,注射用头孢他啶含量测定的结果表示为(99.9±1.92)%,k=2。分析不确定度分量,引出实验室潜在的两个风险点:设备和实验操作因素。结论为有效控制注射用头孢他啶含量测定方法的准确性提供了可靠的理论依据。

DEVELOPMENT OF A NOVEL HPLC METHOD FOR QUALITY CONTROL OF SAFFRON(CROCUS SATIVUS L.)

Saffron,the dried stigma of Crocus sativus L.,findsnumerous applications in TCM.Here,a novel HPLC protocol was established and applied for the analysis of saffron samples,not only from different places of origin but also from several harvest seasons.One of the main active constituents of saffron,crocin,is also contained in

HPLC法测定常山口服溶液的主成分含量

为建立一种同时测定常山口服液中2种主成分的高效液相色谱方法(HPLC),对中药常山及其药物制剂的国家兽药典质量标准提出制修订建议。本研究采用HPLC法,通过方法学验证和不同色谱检测系统的考察,测定常山口服液中常山乙素和常山甲素的含量,明确药物色谱条件的系统适用性要求。包括安捷伦1290型HPLC仪(SB-C_(18)色谱柱)、沃特斯2695型HPLC仪(XTerra@MS C_(18)色谱柱)和岛津SPD-10A型HPLC仪(Amethyst C_(18)-H色谱柱);流动相:乙腈-水-冰醋酸(30∶69.79∶0.21),pH值5.2~6.2,流速:1.0 mL/min,检测波长:265 nm,柱温:25℃,进样量:10μL。三种不同类型的液相系统和色谱柱,所测3批次样品中的主成分含量基本一致,常山甲素和常山乙素的峰型较好,与周围杂质可有效分离。该研究方法可为常山碱口服液质量控制提供参考。

祖师麻中5种成分HPLC同时测定方法的建立

目的:建立HPLC同时测定祖师麻中瑞香素、西瑞香素、黄瑞香苷A、黄瑞香苷B、瑞香新素5种香豆素类成分的含量。方法:采用色谱柱:Agilent 5 TC-C_(18)(250 mm×4.6 mm,5μm);流动相:乙腈(B)-0.1%磷酸水溶液(D);流速:1 mL·min-1;检测波长:320 nm、344 nm;柱温:25℃。结果:瑞香素、西瑞香素、黄瑞香苷A、黄瑞香苷B、瑞香新素的线性范围分别为0.41~208μg/mL(r^(2)=0.9996)、0.34~44μg/mL(r2=0.9995)、0.33~42μg/mL(r^(2)=0.9997)、0.21~220μg/mL(r^(2)=0.9996)、0.33~42μg/mL(r^(2)=0.9992);平均回收率(n=6)分别为96.79%、96.00%、89.40%、91.23%、107.11%。结论:建立了同时测定祖师麻药材中5种香豆素类成分的HPLC,研究结果显示,该方法重复性、稳定性、加样回收等均符合要求,说明该含量测定方法稳定可行,可对祖师麻饮片多成分进行质量控制。

HPLC法检查丙胺卡因原料药有关物质方法研究

目的建立HPLC对丙胺卡因原料药有关物质的测定方法。方法以Waters Xbridge BEH十八烷基硅烷键合硅胶为填充剂(C18,150 mm×4.6 mm×5μm的色谱柱);以磷酸盐缓冲液-乙腈(70∶30)为流动相进行等度洗脱,流速为1.0 mL/min;柱温为25℃;检测波长为240 nm;进样体积20μL。结果溶剂空白对系统适用性各组分测定无干扰,系统适用性中各组分及样品的分离度均达到标准,杂质A、杂质B、杂质C、杂质D、杂质E、杂质F、杂质G的浓度分别在0.10~500.32μg/mL、0.01~51.35μg/mL、0.20~500.51μg/mL、1.00~500.71μg/mL、0.10~499.05μg/mL、0.20~510.45μg/mL、0.10~498.75μg/mL内与其峰面积呈较好的线性关系,其r均在0.9995及以上;平均回收率分别为91.2%、95.9%、96.7%、98.1%、96.5%、97.1%、98.7%,RSD分别为0.68、0.54、0.75、0.36、0.72、0.36、0.61。结论HPLC法检查丙胺卡因原料药有关物质方法具有专属性强、灵敏度高、准确度高、精密度好,可满足丙胺卡因原料药有关物质检测需求。

Development of an HPLC–UV assay method for the simultaneous quantification of nine antiretroviral agents in the plasma of HIV-infected patients

A new method using high-performance liquid chromatography coupled with ultra violet detection(HPLC–UV)was developed and validated for the simultaneous quantification of atazanavir,dolutegravir,darunavir,efavirenz,etravirine lopinavir,raltegravir,rilpivirine and tipranavir in human plasma.For the first time we reported here the development and validation of an HPLC–UV assay to quantify the frequently administered 9antiretroviral compounds including dolutegravir and rilpivirine.A simple solid phase extraction procedure was applied to 500 μL aliquots of plasma.The chromatographic separation of the drugs and internal standard(quinoxaline) was achieved with a gradient of acetonitrile and sodium acetate buffer on a C_(18) reverse-phase analytical column with a 25 min analytical run time.Calibration curves were optimised according to the therapeutic range of drug concentrations in patients,and the coefficient of determination(r^2) was higher than0.99 for all analytes.Mean intraday and interday precisions(RSD) for all compounds were less than 15.0%,and the mean accuracy(% deviation from nominal concentration) was also found to be less than 15.0%.Extraction recovery range was between 80% and 120% for all drugs analysed.The solid phase extraction and HPLC–UV method enable a specific,sensitive,and reliable simultaneous determination of nine antiretroviral agents in plasma.Good extraction efficiency and low limit of HPLC–UV quantification make this method suitable for use in clinical trials and therapeutic drug monitoring.

基于HPLC-IT-TOF/MS分析不同炮制方法对地骨皮化学成分的影响

目的比较不同炮制条件对地骨皮化学成分的影响,优选饮片炮制方法。方法采用HPLC-IT-TOF/MS;ZORBAX SB-Aq C_(18)色谱柱;流动相为0.1%甲酸水溶液-乙腈梯度洗脱;柱温40℃;流速0.3 mL/min;进样体积5μL;电喷雾离子源(Electrospray Ionization,ESI),正、负离子模式下扫描,根据相对分子质量和碎片离子等质谱信息,结合文献信息以及数据库鉴定化学成分,并以各成分的离子峰面积比作为不同炮制品的变化指数进行比较。根据鉴定结果将地骨皮5种主要活性成分的相对含量进行逼近理想解排序法分析(technique for order preference by similarity to ideal solution,TOPSIS),以客观评价经不同炮制方法所得地骨皮的品质。结果共鉴定23种化合物,其中亚麻酸在烘干80℃、焙干100℃时消失,甜菜碱在淘洗2次后消失。地骨皮在不同炮制方法下各成分含量差异较大,随着淘洗次数的增加,地骨皮中成分含量迅速下降;甜菜碱含量随着烘制温度的升高而升高,相反咖啡酰丁二胺含量会随着烘制温度的升高而降低;地骨皮甲素、地骨皮乙素均在50℃烘干时含量最高,绿原酸晒干时含量最高。通过对7种地骨皮样品进行综合评价分析,发现30℃晒干,淘洗1次(S1)为最佳炮制方式。结论地骨皮各炮制品中化合物种类和成分均发生变化;S1为最佳炮制方式。阐明了经不同炮制方法后地骨皮成分变化规律,并为地骨皮质量控制和评价奠定基础。